AstraZeneca Pharma India hits an upper circuit limit of 20% to Rs 885.75 at 12:15 IST on BSE after the company reported a net profit of Rs 1.76 crore in Q1 June 2013 compared with a net loss of Rs 8.14 crore in Q1 June 2012.
The result was announced at the fag end of the trading sessions on Tuesday, 13 August 2013.
Meanwhile, the BSE Sensex was up 62.10 points, or 0.32%, to 19,291.94.
On BSE, 91,390 shares were traded in the counter compared with average volume of 59,176 shares in the past one quarter.
The stock hit a high of Rs 885.75 and a low of Rs 753.65 so far during the day. The stock hit a 52-week high of Rs 1,944 on 27 August 2012. It hit a 52-week low of Rs 595 on 26 March 2013.
The stock had outperformed the market over the past one month till 13 August 2013, rising 9.81% compared with the Sensex's 3.65% decline. The scrip had, however, underperformed the market in past one quarter, sliding 9.40% as against Sensex's 2.35% fall.
The small-cap company has an equity capital of Rs 5 crore. Face value per share is Rs 2.
Net sales rose 37.11% to Rs 125.13 crore in Q1 June 2013 over Q1 June 2012.
AstraZeneca Pharma India is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.
Powered by Capital Market - Live News
